Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Conservative management of young women with endometrial carcinoma or complex atypical hyperplasia: report of three cases and literature review.

Karimi-Zarchi M, Mousavi AS, Behtash N, Chiti Z, Bokaie M.

Eur J Gynaecol Oncol. 2011;32(6):695-8. Review.

PMID:
22335041
2.

Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.

Pronin SM, Novikova OV, Andreeva JY, Novikova EG.

Int J Gynecol Cancer. 2015 Jul;25(6):1010-4. doi: 10.1097/IGC.0000000000000467.

PMID:
25950126
3.

Endometrial adenocarcinoma in young patients: evaluation and fertility-preserving treatment.

Benshushan A.

Eur J Obstet Gynecol Reprod Biol. 2004 Dec 1;117(2):132-7. Review.

PMID:
15541846
4.

Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.

Ricciardi E, Maniglio P, Frega A, Marci R, Caserta D, Moscarini M.

Eur Rev Med Pharmacol Sci. 2012 Dec;16(14):1934-7.

5.

[Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].

Yu M, Shen K, Yang JX, Huang HF, Wu M, Pan LY, Lang JH, Lian LJ.

Zhonghua Fu Chan Ke Za Zhi. 2006 Apr;41(4):242-5. Chinese.

PMID:
16759458
6.
7.

Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.

Gunderson CC, Fader AN, Carson KA, Bristow RE.

Gynecol Oncol. 2012 May;125(2):477-82. doi: 10.1016/j.ygyno.2012.01.003. Epub 2012 Jan 11. Review.

PMID:
22245711
8.

Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.

Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, Hataeg M, Kodama S, Kuzuya K, Sato S, Nishimura T, Hiura M, Nakano H, Iwasaka T, Miyazaki K, Kamura T.

Cancer Lett. 2001 Jun 10;167(1):39-48.

PMID:
11323097
9.

Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy.

Penner KR, Dorigo O, Aoyama C, Ostrzega N, Balzer BL, Rao J, Walsh CS, Cass I, Holschneider CH.

Gynecol Oncol. 2012 Mar;124(3):542-8. doi: 10.1016/j.ygyno.2011.11.004. Epub 2011 Nov 10.

PMID:
22079678
10.

Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.

De Marzi P, Bergamini A, Luchini S, Petrone M, Taccagni GL, Mangili G, Colombo G, Candiani M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(7):1178-82. doi: 10.1016/j.jmig.2015.06.004. Epub 2015 Jun 16.

PMID:
26092080
11.

[Young women with atypical endometrial hyperplasia or endometrial adenocarcinoma stage I: will conservative treatment allow pregnancy? Results of a French multicentric survey].

Le Digabel JF, Gariel C, Catala L, Dhainaut C, Madelenat P, Descamps P.

Gynecol Obstet Fertil. 2006 Jan;34(1):27-33. Epub 2006 Jan 6. French.

PMID:
16406735
12.

[Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].

Cao DY, Yu M, Yang JX, Shen K, Huang HF, Cheng NH, Sun ZY, Deng CY, Yu Q, He FF.

Zhonghua Fu Chan Ke Za Zhi. 2013 Jul;48(7):519-22. Chinese.

PMID:
24284224
13.

[Application of endometrial sampling device during the follow-up visit for the conservative treatment of endometrial cancer].

Zhou R, Shen DH, Wang CH, Geng J, Wang JL, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2013 Dec;48(12):896-8. Chinese.

PMID:
24495680
14.

Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report.

Corrado G, Baiocco E, Carosi M, Vizza E.

Fertil Steril. 2008 Nov;90(5):2006.e5-8. doi: 10.1016/j.fertnstert.2008.06.014. Epub 2008 Aug 9.

PMID:
18692828
15.

Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.

Rubatt JM, Slomovitz BM, Burke TW, Broaddus RR.

Gynecol Oncol. 2005 Nov;99(2):472-6. Epub 2005 Aug 15.

PMID:
16099019
16.

[Modern tendencies in treatment of atypical glandular hyperplasia--our and foreign experience].

Ivanov S, Kovachev E, Tsonev A, Abbud A.

Akush Ginekol (Sofiia). 2010;49(2):47-9. Bulgarian.

PMID:
20734678
17.

Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases.

Signorelli M, Caspani G, Bonazzi C, Chiappa V, Perego P, Mangioni C.

BJOG. 2009 Jan;116(1):114-8. doi: 10.1111/j.1471-0528.2008.02024.x.

18.

Stage IV endometrial cancer after failed conservative management: a case report.

Kothari R, Seamon L, Cohn D, Fowler J, O'Malley DM.

Gynecol Oncol. 2008 Dec;111(3):579-82. doi: 10.1016/j.ygyno.2008.02.027. Epub 2008 Apr 18.

PMID:
18395778
19.

Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.

Witkiewicz AK, McConnell T, Potoczek M, Emmons RV, Kurman RJ.

Hum Pathol. 2010 Jan;41(1):26-32. doi: 10.1016/j.humpath.2009.06.012. Epub 2009 Sep 4.

PMID:
19733383
20.

Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.

Ohyagi-Hara C, Sawada K, Aki I, Mabuchi S, Kobayashi E, Ueda Y, Yoshino K, Fujita M, Tsutsui T, Kimura T.

Arch Gynecol Obstet. 2015 Jan;291(1):151-7. doi: 10.1007/s00404-014-3417-z. Epub 2014 Aug 14. Review.

PMID:
25118836

Supplemental Content

Support Center